Zymeworks Inc.

ZYME Healthcare Biotechnology

Zymeworks Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.0 million, up 38.9% from fiscal 2024. In the quarter to June 2026, revenue fell 90.6%, EPS fell 2,166.7% and free cash flow fell 385.5%, each against the same quarter a year earlier.

25.07 0.68 −2.64%
Market cap
$1.8B
P/E
0.0×
Fwd P/E
16.2×
Dividend yield
—
F-score
7/9
Altman Z
11.56
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

5 6 4 3
ROE
(18.46%) (26.72%) (42.02%) (72.31%)
ROA
(14.34%) (20.04%) (22.72%) (37.25%)
ROIC
(64.78%) (144.67%) 0.00% 0.00%
Return on Tangible Assets
(23.89%) (36.55%) (28.13%) (56.58%)
Average Days of Receivables
79.67 15.98 20.99 58.30
Free Cash Flow per Share
(0.87) (0.47) (1.03) (1.65)
Free Cash Flow
(66.20) (35.36) (77.04) (120.54)
Capital Expenditures
(1.95) (2.35) (1.72) (1.21)
Other line items
Cash ROIC
(11.57%) (7.11%) (14.57%) (34.34%)
Accounts Receivable Turnover
5.07 3.51 5.55 8.67
Accounts Payable Turnover
3.32 2.85 3.97 4.40
Inventory Turnover
0.00 0.00 0.00 0.00
Average Days of Payables
87.99 96.83 81.29 77.87
Days of Inventory on Hand
0.00 0.00 0.00 0.00
Tax Rate
0.13 0.02 (0.01) (0.01)
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
46.30% 58.05% 73.34% 172.33%
Share Based Compensation of Revenue
18.00% 26.46% 35.15% 91.66%
Interest Coverage
— — (6.83) (8.41)
Operating CF/Net income
1.01 0.41 0.73 0.80
Depreciation/Fixed assets
0.81 0.72 0.72 0.68
Capex/Depreciation
(0.15) (0.21) (0.16) (0.13)
Revenue per Share
1.77 1.41 1.09 0.51
Operating CF per Share
(0.85) (0.44) (1.01) (1.63)
Capex per Share
(0.03) (0.03) (0.02) (0.02)
Capex to Sales
0.01 0.02 0.02 0.03

Fold the line items

Columns are period end dates